Owner Investor / Financier Operator Developer Technology licensor Technology / equipment supplier
Asahi Kasei Corporation is a leading Japanese multinational chemical company headquartered in Tokyo. Founded in 1931 as a successor to earlier entities in the chemical sector, it has evolved into a diversified group operating across three main business sectors: Material, Homes, and Healthcare.
The Material sector encompasses chemicals, fibers, electronic materials, battery separators, performance polymers, and related technologies, emphasizing sustainable solutions derived from chemistry expertise. The Homes sector provides order-built residential housing, construction materials, and associated services. Healthcare focuses on pharmaceuticals, medical devices, bioprocess products, and critical care equipment to address unmet medical needs.
The company maintains a global presence with production, sales, and R&D sites in approximately 40 countries, primarily in North America, Asia, and Europe. It employs roughly 48,000 to 50,000 people worldwide. Asahi Kasei Corp. is publicly listed on the Tokyo Stock Exchange (TYO: 3407) and forms part of the Nikkei 225 and TOPIX indices.
Structured as a holding company, the Asahi Kasei Group oversees core operating subsidiaries in each sector, including entities focused on battery separators, pharmaceuticals (such as Asahi Kasei Therapeutics), medical products, and international operations like ZOLL Medical. It ranks among Japan's top chemical manufacturers by revenue and positions itself as an innovator contributing to societal needs under the slogan "Creating for Tomorrow."
Also known as Asahi Kasei Battery Separator America, LLC, Asahi Kasei Pharma Corporation, Asahi Kasei Corp., Asahi Kasei Medical Co., Ltd., 旭化成ファーマ株式会社 and 10 more.
chemXplore tracks 8 projects involving Asahi Kasei, of which 6 are active.
Besides these 6, the record holds 2 completed projects.
Closest to start-up first.
1 more active project and the 2 that are completed, on hold or cancelled are in the record. See all 8 in chemXplore →
1 active project carries no start-up date yet. The dates themselves, per project, are for subscribers.
Oral helicase‑primase inhibitor pritelivir is the first novel‑mechanism FDA‑approved HSV therapy in ~30 years; Phase 3 showed 63% vs 34% healing by Day 28. US availability expected before end of 2026.
First patient dosed in a randomized Phase 2a trial of AIC468, an antisense oligonucleotide targeting BK virus in adult kidney transplant recipients.
New merged textile/materials unit formed with 80/20 ownership split, 2.0 billion yen capital and Osaka base; integration already reflected in FY ending March 31, 2027 forecast.
Brings acquired specialty-pharma units into a single global management to pursue niche immunology, nephrology, transplant and infectious disease markets; targets ¥300bn by FY2030.
USD>800M CA‑EDC plant at 80% completion; main equipment being installed; start planned for 2027; capacities 827 kt caustic soda and 500 kt EDC with significant import substitution and export potential.
Automated single‑use benchtop virus filtration for lab‑scale and process development; supports Planova 35N filters and will be shown at BPI East (Booth 606).
Phase II study in Japanese children (1–17 years) to evaluate safety and pharmacokinetics of isavuconazonium sulfate for invasive fungal infections.
Phase 2 trial compares pegrizeprument with tacrolimus in up to 120 de novo kidney transplant recipients; primary endpoints are safety, pharmacokinetics and pharmacodynamics.
